Evidence map›Paper›PMID 36174572›Full record

ArticleNeuron2022

Myeloid cell interferon secretion restricts Zika flavivirus infection of developing and malignant human neural progenitor cells.

Harry Bulstrode, Gemma C Girdler, Tannia Gracia, Alexander Aivazidis, Ilias Moutsopoulos, Adam M H Young, John Hancock, Xiaoling He, Katherine Ridley, Zhaoyang Xu and 21 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuron, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Genetically modified ZIKA virus as a microRNA-sensitive oncolytic virus against central nervous system tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 8 institutions in 1 country.

Harry BulstrodeWellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Division of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK. Electronic address: hb252@cam.ac.uk.
Gemma C GirdlerWellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Division of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.
Tannia GraciaCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Alexander AivazidisWellcome Sanger Institute, Hinxton CB10 1SA, UK.
Ilias MoutsopoulosWellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK.
Adam M H YoungWellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Division of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.
John HancockCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
Xiaoling HeWellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK.
Katherine RidleyWellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Department of Paediatrics, University of Cambridge, Cambridge CB2 0QQ, UK.
Zhaoyang XuWellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Department of Paediatrics, University of Cambridge, Cambridge CB2 0QQ, UK.
John H StockleyWellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Department of Paediatrics, University of Cambridge, Cambridge CB2 0QQ, UK.
John FinlayWellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Department of Paediatrics, University of Cambridge, Cambridge CB2 0QQ, UK.
Clement HallouWellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Department of Paediatrics, University of Cambridge, Cambridge CB2 0QQ, UK.
Teodoro FajardoDepartment of Virology, University of Cambridge, Cambridge CB2 0QQ, UK; Department of Virology, Royal London Hospital, Barts Health NHS Trust, London E1 2ES, UK.
Daniel M FountainManchester Centre for Clinical Neurosciences, Manchester M6 8HD, UK.
Stijn van DongenWellcome Sanger Institute, Hinxton CB10 1SA, UK.
Alexis JoannidesDivision of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.
Robert MorrisDivision of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.
Richard MairDivision of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.
Colin WattsInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2SY, UK.
Thomas SantariusDivision of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.
Stephen J PriceDivision of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.
Peter J A HutchinsonDivision of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.
Emma J HodsonExperimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge CB2 0QQ, UK.
Steven M PollardCentre for Regenerative Medicine and Cancer Research UK Edinburgh Centre, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK.
Irina MohorianuWellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK.
Roger A BarkerWellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK.
Trevor R SweeneyDepartment of Virology, University of Cambridge, Cambridge CB2 0QQ, UK; The Pirbright Institute, Guildford, Surrey GU24 0NF, UK.
Omer BayraktarWellcome Sanger Institute, Hinxton CB10 1SA, UK.
Fanni GergelyCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK. Electronic address: fanni.gergely@bioch.ox.ac.uk.
David H RowitchWellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Wellcome Sanger Institute, Hinxton CB10 1SA, UK; Department of Paediatrics, University of Cambridge, Cambridge CB2 0QQ, UK. Electronic address: dhr25@medschl.cam.ac.uk.
Wellcome/MRC Cambridge Stem Cell Institute · GBUniversity of Cambridge · GBWellcome Sanger Institute · GBBarts Health NHS Trust · GBEdinburgh Cancer Research · GBNIHR Manchester Biomedical Research Centre · GBThe Pirbright Institute · GBUniversity of Birmingham · GB

Funding

Biotechnology and Biological Sciences Research Council BBS/E/I/00007031Cancer Research UK 21992Cancer Research UK 24455Cancer Research UK 28592Medical Research Council MC_PC_17230Wellcome Trust 108139Wellcome Trust 202471Wellcome Trust 202471/Z/16/ZWellcome Trust 223011
6 · The paper itself

Abstract

Zika virus (ZIKV) can infect human developing brain (HDB) progenitors resulting in epidemic microcephaly, whereas analogous cellular tropism offers treatment potential for the adult brain cancer, glioblastoma (GBM). We compared productive ZIKV infection in HDB and GBM primary tissue explants that both contain SOX2+ neural progenitors. Strikingly, although the HDB proved uniformly vulnerable to ZIKV infection, GBM was more refractory, and this correlated with an innate immune expression signature. Indeed, GBM-derived CD11b+ microglia/macrophages were necessary and sufficient to protect progenitors against ZIKV infection in a non-cell autonomous manner. Using SOX2+ GBM cell lines, we found that CD11b+-conditioned medium containing type 1 interferon beta (IFNβ) promoted progenitor resistance to ZIKV, whereas inhibition of JAK1/2 signaling restored productive infection. Additionally, CD11b+ conditioned medium, and IFNβ treatment rendered HDB progenitor lines and explants refractory to ZIKV. These findings provide insight into neuroprotection for HDB progenitors as well as enhanced GBM oncolytic therapies.

Indexed as

Zika VirusZika Virus InfectionHumansInterferonsMyeloid CellsStem CellsInterferonsflavivirusGBMglioblastomainterferonmacrophagemicrogliamyeloidneuraloncolyticZika

Identifiers

PMID36174572
PMCPMC7615581
OpenAlexW4297496628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.